Andrew Donson
Concepts (416)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ependymoma | 26 | 2024 | 175 | 5.430 |
Why?
| Brain Neoplasms | 40 | 2024 | 1137 | 4.010 |
Why?
| Infratentorial Neoplasms | 7 | 2024 | 59 | 2.260 |
Why?
| Glioma | 15 | 2024 | 348 | 1.800 |
Why?
| Medulloblastoma | 15 | 2023 | 192 | 1.650 |
Why?
| Astrocytoma | 12 | 2023 | 120 | 1.620 |
Why?
| Gene Expression Regulation, Neoplastic | 25 | 2024 | 1315 | 1.560 |
Why?
| Glioblastoma | 14 | 2019 | 311 | 1.480 |
Why?
| Craniopharyngioma | 7 | 2024 | 82 | 1.440 |
Why?
| Brain Stem Neoplasms | 9 | 2023 | 87 | 1.380 |
Why?
| Gene Expression Profiling | 26 | 2024 | 1696 | 1.340 |
Why?
| Cerebellar Neoplasms | 9 | 2023 | 150 | 1.200 |
Why?
| Pituitary Neoplasms | 5 | 2024 | 184 | 1.110 |
Why?
| Rhabdoid Tumor | 10 | 2022 | 85 | 1.000 |
Why?
| Central Nervous System Neoplasms | 9 | 2021 | 147 | 0.950 |
Why?
| Ganglioglioma | 4 | 2017 | 31 | 0.810 |
Why?
| Biomarkers, Tumor | 12 | 2024 | 1171 | 0.800 |
Why?
| Drug Screening Assays, Antitumor | 5 | 2021 | 195 | 0.740 |
Why?
| Proto-Oncogene Proteins B-raf | 5 | 2017 | 210 | 0.740 |
Why?
| Neoplastic Cells, Circulating | 1 | 2020 | 67 | 0.670 |
Why?
| Transcriptome | 10 | 2023 | 872 | 0.660 |
Why?
| Radiation Tolerance | 6 | 2022 | 97 | 0.660 |
Why?
| Neoplasm Recurrence, Local | 8 | 2021 | 952 | 0.660 |
Why?
| Cell Line, Tumor | 25 | 2022 | 3106 | 0.640 |
Why?
| Single-Cell Analysis | 2 | 2021 | 265 | 0.620 |
Why?
| Cyst Fluid | 1 | 2017 | 27 | 0.570 |
Why?
| Child | 48 | 2024 | 20963 | 0.570 |
Why?
| Antineoplastic Agents | 7 | 2022 | 2039 | 0.550 |
Why?
| Oligonucleotide Array Sequence Analysis | 19 | 2016 | 773 | 0.520 |
Why?
| Radiation | 3 | 2021 | 24 | 0.510 |
Why?
| Teratoma | 6 | 2022 | 102 | 0.510 |
Why?
| Cell Cycle Proteins | 6 | 2022 | 577 | 0.500 |
Why?
| Chromosomes, Human, Pair 1 | 3 | 2020 | 72 | 0.470 |
Why?
| Humans | 99 | 2024 | 129705 | 0.470 |
Why?
| Cancer Vaccines | 2 | 2010 | 164 | 0.450 |
Why?
| DNA Methylation | 7 | 2021 | 601 | 0.440 |
Why?
| Child, Preschool | 29 | 2021 | 10565 | 0.410 |
Why?
| Tumor Microenvironment | 6 | 2023 | 592 | 0.410 |
Why?
| Radiation-Sensitizing Agents | 3 | 2016 | 40 | 0.380 |
Why?
| Cytokines | 4 | 2018 | 2008 | 0.370 |
Why?
| Neoplasm Proteins | 3 | 2012 | 429 | 0.360 |
Why?
| Cell Proliferation | 17 | 2022 | 2340 | 0.360 |
Why?
| Neoplasms, Neuroepithelial | 2 | 2021 | 17 | 0.350 |
Why?
| Survivors | 2 | 2023 | 458 | 0.350 |
Why?
| Tumor Suppressor Proteins | 2 | 2017 | 314 | 0.350 |
Why?
| Chromosome Aberrations | 2 | 2023 | 148 | 0.340 |
Why?
| Prognosis | 15 | 2023 | 3801 | 0.340 |
Why?
| Apoptosis | 14 | 2022 | 2485 | 0.330 |
Why?
| Supratentorial Neoplasms | 2 | 2021 | 18 | 0.330 |
Why?
| Histones | 4 | 2021 | 585 | 0.330 |
Why?
| Protein-Tyrosine Kinases | 4 | 2019 | 421 | 0.320 |
Why?
| Proto-Oncogene Proteins | 5 | 2022 | 636 | 0.310 |
Why?
| Microarray Analysis | 7 | 2017 | 122 | 0.310 |
Why?
| Oncogene Proteins, Fusion | 2 | 2021 | 195 | 0.310 |
Why?
| Quinazolines | 3 | 2022 | 245 | 0.310 |
Why?
| Drug Resistance, Neoplasm | 5 | 2017 | 733 | 0.300 |
Why?
| Pyrimidines | 6 | 2017 | 444 | 0.300 |
Why?
| Nuclear Proteins | 4 | 2017 | 644 | 0.300 |
Why?
| MAP Kinase Signaling System | 2 | 2021 | 305 | 0.290 |
Why?
| Mutation | 7 | 2021 | 3674 | 0.290 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2020 | 1570 | 0.280 |
Why?
| DNA Modification Methylases | 1 | 2007 | 17 | 0.280 |
Why?
| DNA Repair Enzymes | 1 | 2007 | 25 | 0.280 |
Why?
| Chemoradiotherapy | 2 | 2019 | 207 | 0.270 |
Why?
| Antineoplastic Agents, Alkylating | 1 | 2007 | 70 | 0.270 |
Why?
| Dacarbazine | 1 | 2007 | 99 | 0.270 |
Why?
| Cyclin-Dependent Kinase 6 | 2 | 2020 | 39 | 0.270 |
Why?
| Chromosomes | 2 | 2024 | 100 | 0.270 |
Why?
| B7-H1 Antigen | 2 | 2018 | 174 | 0.260 |
Why?
| RNA, Messenger | 8 | 2017 | 2705 | 0.260 |
Why?
| Immunohistochemistry | 6 | 2017 | 1700 | 0.250 |
Why?
| Infant | 17 | 2020 | 9097 | 0.250 |
Why?
| Tumor Cells, Cultured | 8 | 2019 | 929 | 0.250 |
Why?
| Chloroquine | 2 | 2017 | 53 | 0.250 |
Why?
| Kaplan-Meier Estimate | 5 | 2021 | 863 | 0.240 |
Why?
| Cellular Senescence | 2 | 2024 | 176 | 0.240 |
Why?
| Cisplatin | 3 | 2016 | 292 | 0.240 |
Why?
| DNA, Neoplasm | 2 | 2020 | 162 | 0.230 |
Why?
| Adolescent | 23 | 2021 | 20355 | 0.230 |
Why?
| NF-kappa B | 2 | 2020 | 687 | 0.230 |
Why?
| Immunophenotyping | 2 | 2017 | 311 | 0.230 |
Why?
| Neoplasms, Radiation-Induced | 3 | 2010 | 71 | 0.230 |
Why?
| Molecular Targeted Therapy | 3 | 2018 | 381 | 0.230 |
Why?
| Neurofibroma, Plexiform | 1 | 2023 | 8 | 0.220 |
Why?
| Male | 35 | 2024 | 63544 | 0.220 |
Why?
| Neurofibromatosis 1 | 1 | 2023 | 44 | 0.210 |
Why?
| Pyrazoles | 5 | 2022 | 403 | 0.210 |
Why?
| Autophagy | 2 | 2017 | 264 | 0.210 |
Why?
| Female | 35 | 2024 | 68561 | 0.210 |
Why?
| Transcription Factors | 5 | 2023 | 1636 | 0.210 |
Why?
| Receptor, Platelet-Derived Growth Factor alpha | 2 | 2021 | 48 | 0.210 |
Why?
| Epigenesis, Genetic | 4 | 2021 | 614 | 0.210 |
Why?
| Survival Analysis | 3 | 2023 | 1297 | 0.200 |
Why?
| Indoles | 2 | 2017 | 379 | 0.200 |
Why?
| Tamoxifen | 2 | 2004 | 199 | 0.200 |
Why?
| Cell Survival | 8 | 2020 | 1083 | 0.200 |
Why?
| raf Kinases | 1 | 2021 | 11 | 0.190 |
Why?
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2021 | 16 | 0.190 |
Why?
| Sulfonamides | 2 | 2017 | 494 | 0.190 |
Why?
| Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 60 | 0.190 |
Why?
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 67 | 0.190 |
Why?
| Receptor, ErbB-3 | 2 | 2015 | 45 | 0.190 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2023 | 191 | 0.190 |
Why?
| Vaccination | 1 | 2010 | 1362 | 0.190 |
Why?
| Cell Cycle | 8 | 2017 | 581 | 0.190 |
Why?
| Cohort Studies | 9 | 2021 | 5410 | 0.180 |
Why?
| Receptor, trkC | 1 | 2021 | 10 | 0.180 |
Why?
| Gene Amplification | 1 | 2021 | 102 | 0.180 |
Why?
| Receptors, Fibroblast Growth Factor | 1 | 2021 | 65 | 0.180 |
Why?
| Receptor, trkB | 1 | 2021 | 31 | 0.180 |
Why?
| Gene Expression | 4 | 2015 | 1477 | 0.180 |
Why?
| Jumonji Domain-Containing Histone Demethylases | 1 | 2021 | 60 | 0.170 |
Why?
| Polycomb Repressive Complex 1 | 1 | 2020 | 46 | 0.170 |
Why?
| B7 Antigens | 1 | 2020 | 14 | 0.170 |
Why?
| DNA-Binding Proteins | 3 | 2021 | 1423 | 0.170 |
Why?
| Anilides | 2 | 2010 | 72 | 0.170 |
Why?
| Diagnosis, Computer-Assisted | 1 | 2020 | 85 | 0.170 |
Why?
| Mice | 12 | 2024 | 16585 | 0.170 |
Why?
| Cell Transformation, Neoplastic | 3 | 2019 | 322 | 0.170 |
Why?
| Phenotype | 5 | 2024 | 3063 | 0.160 |
Why?
| MicroRNAs | 2 | 2020 | 671 | 0.160 |
Why?
| Machine Learning | 1 | 2024 | 419 | 0.160 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2012 | 962 | 0.160 |
Why?
| Cell Lineage | 1 | 2021 | 333 | 0.160 |
Why?
| Lymphocytes, Tumor-Infiltrating | 2 | 2012 | 203 | 0.160 |
Why?
| Genome, Human | 3 | 2021 | 394 | 0.160 |
Why?
| SMARCB1 Protein | 1 | 2019 | 17 | 0.160 |
Why?
| Pteridines | 2 | 2016 | 22 | 0.160 |
Why?
| Infant, Newborn | 8 | 2020 | 5752 | 0.150 |
Why?
| Protein Kinase C | 1 | 2000 | 259 | 0.150 |
Why?
| Membrane Glycoproteins | 1 | 2021 | 466 | 0.150 |
Why?
| Dose-Response Relationship, Drug | 6 | 2017 | 1969 | 0.150 |
Why?
| Aging | 2 | 2020 | 1769 | 0.150 |
Why?
| Stromal Cells | 1 | 2018 | 104 | 0.150 |
Why?
| ErbB Receptors | 2 | 2015 | 601 | 0.150 |
Why?
| Meningioma | 2 | 2009 | 78 | 0.150 |
Why?
| Adenoviridae | 1 | 1998 | 195 | 0.150 |
Why?
| SOXE Transcription Factors | 2 | 2016 | 18 | 0.150 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2022 | 509 | 0.150 |
Why?
| Proto-Oncogene Proteins c-myc | 1 | 2019 | 124 | 0.140 |
Why?
| Drug Approval | 1 | 2018 | 88 | 0.140 |
Why?
| Computer Simulation | 2 | 2021 | 947 | 0.140 |
Why?
| Receptors, Interleukin-6 | 1 | 2017 | 36 | 0.140 |
Why?
| Everolimus | 1 | 2017 | 69 | 0.140 |
Why?
| Transcription Factor RelA | 1 | 2018 | 85 | 0.140 |
Why?
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 50 | 0.140 |
Why?
| Genes, p16 | 1 | 2017 | 20 | 0.140 |
Why?
| E2F Transcription Factors | 1 | 2017 | 59 | 0.140 |
Why?
| Spinal Neoplasms | 1 | 2017 | 29 | 0.140 |
Why?
| Morpholines | 1 | 2017 | 126 | 0.140 |
Why?
| Stem Cells | 1 | 2021 | 572 | 0.140 |
Why?
| Genetic Therapy | 1 | 1998 | 295 | 0.130 |
Why?
| Checkpoint Kinase 1 | 1 | 2016 | 30 | 0.130 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2018 | 227 | 0.130 |
Why?
| Gene Expression Regulation, Developmental | 1 | 2021 | 819 | 0.130 |
Why?
| Retrospective Studies | 11 | 2020 | 14669 | 0.130 |
Why?
| Image Processing, Computer-Assisted | 1 | 2020 | 739 | 0.130 |
Why?
| Bone Morphogenetic Proteins | 2 | 2019 | 131 | 0.130 |
Why?
| Blotting, Western | 6 | 2013 | 1189 | 0.130 |
Why?
| Myeloid Cells | 2 | 2015 | 141 | 0.130 |
Why?
| EGF Family of Proteins | 1 | 2015 | 17 | 0.120 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 418 | 0.120 |
Why?
| Animals | 13 | 2024 | 34733 | 0.120 |
Why?
| Young Adult | 9 | 2021 | 12363 | 0.120 |
Why?
| Neuroectodermal Tumors, Primitive | 2 | 2012 | 11 | 0.120 |
Why?
| Receptor, EphA2 | 1 | 2015 | 19 | 0.120 |
Why?
| Flow Cytometry | 3 | 2006 | 1151 | 0.120 |
Why?
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2015 | 21 | 0.120 |
Why?
| Disease Models, Animal | 3 | 2021 | 4016 | 0.120 |
Why?
| Pilomatrixoma | 1 | 2015 | 3 | 0.120 |
Why?
| Proteins | 1 | 2021 | 948 | 0.120 |
Why?
| Radiation, Ionizing | 2 | 2012 | 75 | 0.120 |
Why?
| Mutation, Missense | 1 | 2016 | 319 | 0.120 |
Why?
| src-Family Kinases | 1 | 2015 | 94 | 0.120 |
Why?
| Genetic Variation | 1 | 2019 | 936 | 0.120 |
Why?
| Activin Receptors, Type I | 1 | 2014 | 7 | 0.110 |
Why?
| Drug Delivery Systems | 2 | 2015 | 328 | 0.110 |
Why?
| Follow-Up Studies | 6 | 2020 | 4939 | 0.110 |
Why?
| Adult | 16 | 2023 | 35595 | 0.110 |
Why?
| Deoxyribose | 1 | 2013 | 5 | 0.110 |
Why?
| STAT3 Transcription Factor | 1 | 2015 | 187 | 0.110 |
Why?
| Glutamate-Cysteine Ligase | 1 | 2013 | 18 | 0.110 |
Why?
| RNA-Binding Proteins | 2 | 2015 | 382 | 0.110 |
Why?
| Survival Rate | 4 | 2020 | 1894 | 0.100 |
Why?
| Exons | 1 | 2013 | 330 | 0.100 |
Why?
| Karyotyping | 4 | 2010 | 107 | 0.100 |
Why?
| Karnofsky Performance Status | 1 | 2012 | 39 | 0.100 |
Why?
| Acetylcysteine | 1 | 2013 | 148 | 0.100 |
Why?
| Receptors, Opioid | 1 | 2012 | 20 | 0.100 |
Why?
| Isocitrate Dehydrogenase | 1 | 2012 | 48 | 0.100 |
Why?
| Pons | 1 | 2012 | 30 | 0.100 |
Why?
| Combined Modality Therapy | 4 | 2019 | 1213 | 0.100 |
Why?
| Central Nervous System | 1 | 2014 | 255 | 0.100 |
Why?
| Tomography, X-Ray Computed | 2 | 2020 | 2539 | 0.100 |
Why?
| Protein Precursors | 1 | 2012 | 126 | 0.090 |
Why?
| Age Factors | 2 | 2017 | 3145 | 0.090 |
Why?
| Interleukin-6 | 1 | 2015 | 715 | 0.090 |
Why?
| RNA, Small Interfering | 2 | 2010 | 575 | 0.090 |
Why?
| Databases, Factual | 1 | 2016 | 1297 | 0.090 |
Why?
| T-Lymphocytes, Cytotoxic | 1 | 2011 | 166 | 0.090 |
Why?
| Protein Kinase Inhibitors | 3 | 2014 | 870 | 0.090 |
Why?
| Drug Synergism | 3 | 2017 | 354 | 0.090 |
Why?
| Acetaminophen | 1 | 2013 | 255 | 0.090 |
Why?
| Epigenomics | 2 | 2021 | 111 | 0.090 |
Why?
| Risk Factors | 4 | 2020 | 9832 | 0.090 |
Why?
| Cluster Analysis | 3 | 2021 | 482 | 0.090 |
Why?
| Magnetic Resonance Imaging | 2 | 2020 | 3351 | 0.080 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2011 | 206 | 0.080 |
Why?
| Neoplasm Grading | 2 | 2021 | 278 | 0.080 |
Why?
| Poly(ADP-ribose) Polymerases | 1 | 2009 | 89 | 0.080 |
Why?
| Peripheral Nervous System Neoplasms | 1 | 2009 | 20 | 0.080 |
Why?
| Astrocytes | 1 | 2011 | 186 | 0.080 |
Why?
| Spinal Cord Neoplasms | 1 | 2009 | 39 | 0.080 |
Why?
| T-Lymphocytes | 2 | 2018 | 1911 | 0.080 |
Why?
| Hemangioma | 1 | 2009 | 44 | 0.080 |
Why?
| Proportional Hazards Models | 1 | 2012 | 1227 | 0.080 |
Why?
| Gene Ontology | 2 | 2021 | 49 | 0.080 |
Why?
| Kidney Neoplasms | 1 | 2013 | 352 | 0.080 |
Why?
| Enzyme Inhibitors | 4 | 2012 | 828 | 0.080 |
Why?
| Sarcoma, Ewing | 1 | 2009 | 86 | 0.070 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2010 | 234 | 0.070 |
Why?
| Glucose | 1 | 2013 | 977 | 0.070 |
Why?
| Herpesvirus 3, Human | 1 | 2011 | 398 | 0.070 |
Why?
| Meningeal Neoplasms | 1 | 2008 | 89 | 0.070 |
Why?
| Nerve Sheath Neoplasms | 1 | 2007 | 8 | 0.070 |
Why?
| Mesenchymoma | 1 | 2007 | 7 | 0.070 |
Why?
| DNA Copy Number Variations | 2 | 2021 | 172 | 0.070 |
Why?
| Herpes Zoster | 1 | 2011 | 349 | 0.070 |
Why?
| Phosphorylation | 3 | 2017 | 1687 | 0.070 |
Why?
| Aurora Kinases | 3 | 2012 | 29 | 0.070 |
Why?
| Etoposide | 1 | 2007 | 148 | 0.070 |
Why?
| Real-Time Polymerase Chain Reaction | 3 | 2012 | 328 | 0.070 |
Why?
| Thymidine | 1 | 2006 | 58 | 0.070 |
Why?
| Aurora Kinase A | 3 | 2012 | 55 | 0.070 |
Why?
| Xenograft Model Antitumor Assays | 2 | 2019 | 797 | 0.070 |
Why?
| High Mobility Group Proteins | 1 | 2006 | 42 | 0.070 |
Why?
| Gene Silencing | 1 | 2007 | 180 | 0.070 |
Why?
| Dose-Response Relationship, Radiation | 2 | 2012 | 131 | 0.060 |
Why?
| Chromatin | 2 | 2020 | 470 | 0.060 |
Why?
| Piperazines | 2 | 2022 | 327 | 0.060 |
Why?
| Cell Differentiation | 3 | 2020 | 1858 | 0.060 |
Why?
| Nerve Tissue Proteins | 1 | 2009 | 568 | 0.060 |
Why?
| Azepines | 2 | 2019 | 87 | 0.060 |
Why?
| Coculture Techniques | 2 | 2011 | 217 | 0.060 |
Why?
| Fatal Outcome | 2 | 2021 | 301 | 0.060 |
Why?
| In Situ Hybridization, Fluorescence | 3 | 2012 | 319 | 0.060 |
Why?
| Computational Biology | 2 | 2020 | 588 | 0.060 |
Why?
| Treatment Outcome | 3 | 2024 | 10299 | 0.060 |
Why?
| Benzamides | 2 | 2017 | 191 | 0.060 |
Why?
| Pyrimidinones | 2 | 2016 | 102 | 0.060 |
Why?
| Cell Division | 2 | 2010 | 802 | 0.060 |
Why?
| Signal Transduction | 2 | 2015 | 4863 | 0.060 |
Why?
| X-ray Repair Cross Complementing Protein 1 | 1 | 2023 | 14 | 0.060 |
Why?
| Intelligence Tests | 1 | 2023 | 59 | 0.050 |
Why?
| RNA, Small Nuclear | 1 | 2023 | 35 | 0.050 |
Why?
| Cranial Irradiation | 1 | 2023 | 68 | 0.050 |
Why?
| Quality of Life | 1 | 2015 | 2712 | 0.050 |
Why?
| Fluorouracil | 1 | 2024 | 198 | 0.050 |
Why?
| Proto-Oncogene Proteins c-sis | 1 | 2023 | 34 | 0.050 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2004 | 157 | 0.050 |
Why?
| Genomics | 2 | 2021 | 716 | 0.050 |
Why?
| Caspases | 1 | 2004 | 249 | 0.050 |
Why?
| Up-Regulation | 2 | 2016 | 850 | 0.050 |
Why?
| Membrane Proteins | 1 | 2009 | 1108 | 0.050 |
Why?
| Cytidine Deaminase | 1 | 2023 | 57 | 0.050 |
Why?
| RNA | 2 | 2023 | 877 | 0.050 |
Why?
| Middle Aged | 7 | 2021 | 31103 | 0.050 |
Why?
| Brain Stem | 1 | 2023 | 95 | 0.050 |
Why?
| Transcription, Genetic | 2 | 2021 | 1409 | 0.050 |
Why?
| G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 45 | 0.050 |
Why?
| Sequence Analysis, DNA | 2 | 2016 | 784 | 0.050 |
Why?
| Septum Pellucidum | 1 | 2021 | 5 | 0.050 |
Why?
| Cerebellum | 1 | 2023 | 216 | 0.050 |
Why?
| Pancreatic Neoplasms | 1 | 2009 | 881 | 0.050 |
Why?
| Sensitivity and Specificity | 1 | 2006 | 1849 | 0.050 |
Why?
| Ligands | 1 | 2023 | 615 | 0.050 |
Why?
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2021 | 14 | 0.050 |
Why?
| Mesencephalon | 1 | 2021 | 66 | 0.050 |
Why?
| Histone Deacetylases | 1 | 2023 | 211 | 0.050 |
Why?
| Chromosome Deletion | 1 | 2021 | 104 | 0.050 |
Why?
| Drug Evaluation, Preclinical | 2 | 2013 | 173 | 0.050 |
Why?
| Disease Progression | 2 | 2023 | 2612 | 0.050 |
Why?
| Neoplasm Staging | 2 | 2017 | 1286 | 0.050 |
Why?
| Genetic Heterogeneity | 1 | 2021 | 54 | 0.050 |
Why?
| DNA Damage | 2 | 2016 | 377 | 0.050 |
Why?
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2021 | 50 | 0.050 |
Why?
| Gene Rearrangement | 1 | 2021 | 151 | 0.040 |
Why?
| Hedgehog Proteins | 1 | 2022 | 187 | 0.040 |
Why?
| Metabolic Networks and Pathways | 1 | 2021 | 176 | 0.040 |
Why?
| Preoperative Period | 1 | 2020 | 113 | 0.040 |
Why?
| Vinblastine | 1 | 2020 | 69 | 0.040 |
Why?
| Cell Fusion | 1 | 2020 | 51 | 0.040 |
Why?
| Carboplatin | 1 | 2020 | 140 | 0.040 |
Why?
| Signal-To-Noise Ratio | 1 | 2020 | 62 | 0.040 |
Why?
| Repressor Proteins | 1 | 2023 | 400 | 0.040 |
Why?
| RNA, Neoplasm | 2 | 2009 | 89 | 0.040 |
Why?
| Cytotoxicity Tests, Immunologic | 1 | 1998 | 43 | 0.040 |
Why?
| Neuropsychological Tests | 1 | 2023 | 996 | 0.040 |
Why?
| Mice, SCID | 1 | 2019 | 343 | 0.040 |
Why?
| Cell Self Renewal | 1 | 2019 | 50 | 0.040 |
Why?
| Pyridines | 2 | 2012 | 472 | 0.040 |
Why?
| Protein Isoforms | 1 | 2000 | 369 | 0.040 |
Why?
| Benchmarking | 1 | 2020 | 175 | 0.040 |
Why?
| Odontogenesis | 1 | 2018 | 11 | 0.040 |
Why?
| Lysine | 1 | 2020 | 266 | 0.040 |
Why?
| Laser Capture Microdissection | 1 | 2018 | 23 | 0.040 |
Why?
| In Vitro Techniques | 1 | 2020 | 1063 | 0.040 |
Why?
| Tissue Culture Techniques | 1 | 2018 | 70 | 0.040 |
Why?
| Mice, Inbred NOD | 1 | 2019 | 579 | 0.040 |
Why?
| Treatment Failure | 1 | 1999 | 347 | 0.040 |
Why?
| Receptors, HIV | 1 | 2017 | 26 | 0.040 |
Why?
| Mucin-1 | 1 | 2017 | 20 | 0.040 |
Why?
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2017 | 59 | 0.040 |
Why?
| Cytogenetic Analysis | 1 | 2017 | 34 | 0.040 |
Why?
| Down-Regulation | 1 | 2000 | 637 | 0.040 |
Why?
| Fluorescent Antibody Technique | 1 | 2018 | 393 | 0.040 |
Why?
| Genetic Vectors | 1 | 1998 | 315 | 0.040 |
Why?
| Immune System | 1 | 1998 | 177 | 0.040 |
Why?
| Pituitary Gland | 1 | 2018 | 147 | 0.040 |
Why?
| Triazoles | 1 | 2019 | 153 | 0.040 |
Why?
| HEK293 Cells | 1 | 2020 | 673 | 0.040 |
Why?
| Interleukin-2 | 1 | 1998 | 433 | 0.030 |
Why?
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 114 | 0.030 |
Why?
| Ki-67 Antigen | 1 | 2017 | 109 | 0.030 |
Why?
| Mice, Nude | 1 | 2019 | 680 | 0.030 |
Why?
| Neuroglia | 1 | 2018 | 165 | 0.030 |
Why?
| Glial Fibrillary Acidic Protein | 1 | 2017 | 92 | 0.030 |
Why?
| Cetuximab | 1 | 2017 | 93 | 0.030 |
Why?
| Models, Theoretical | 1 | 2020 | 551 | 0.030 |
Why?
| Benzodiazepinones | 1 | 2016 | 16 | 0.030 |
Why?
| M Phase Cell Cycle Checkpoints | 1 | 2016 | 24 | 0.030 |
Why?
| Camptothecin | 1 | 2017 | 106 | 0.030 |
Why?
| Diagnosis, Differential | 2 | 2012 | 1442 | 0.030 |
Why?
| Genes, myc | 1 | 2016 | 48 | 0.030 |
Why?
| Immune Tolerance | 1 | 1998 | 348 | 0.030 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 484 | 0.030 |
Why?
| Urea | 1 | 2016 | 75 | 0.030 |
Why?
| Microscopy, Confocal | 1 | 2017 | 308 | 0.030 |
Why?
| Antigens, CD | 1 | 1998 | 479 | 0.030 |
Why?
| Mice, Transgenic | 1 | 2021 | 2075 | 0.030 |
Why?
| Thiophenes | 1 | 2016 | 118 | 0.030 |
Why?
| Amino Acid Substitution | 1 | 2016 | 281 | 0.030 |
Why?
| Sequence Analysis, RNA | 1 | 2018 | 423 | 0.030 |
Why?
| T-Lymphocytes, Regulatory | 1 | 1998 | 380 | 0.030 |
Why?
| Transcriptional Activation | 1 | 2017 | 360 | 0.030 |
Why?
| Amphiregulin | 1 | 2015 | 25 | 0.030 |
Why?
| Mitosis | 1 | 2016 | 177 | 0.030 |
Why?
| Recombinant Proteins | 1 | 1998 | 1306 | 0.030 |
Why?
| Gene Fusion | 1 | 2015 | 23 | 0.030 |
Why?
| Cell Culture Techniques | 1 | 2017 | 355 | 0.030 |
Why?
| HeLa Cells | 1 | 2016 | 602 | 0.030 |
Why?
| Disease-Free Survival | 1 | 2016 | 658 | 0.030 |
Why?
| Lipopolysaccharide Receptors | 1 | 2015 | 90 | 0.030 |
Why?
| Gene Dosage | 1 | 2015 | 143 | 0.030 |
Why?
| Aged | 4 | 2016 | 22113 | 0.030 |
Why?
| Inhibitor of Differentiation Protein 1 | 1 | 2014 | 6 | 0.030 |
Why?
| Inhibitor of Differentiation Protein 2 | 1 | 2014 | 5 | 0.030 |
Why?
| Smad Proteins | 1 | 2014 | 38 | 0.030 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2013 | 65 | 0.030 |
Why?
| Receptors, IgG | 1 | 2013 | 73 | 0.030 |
Why?
| Imaging, Three-Dimensional | 1 | 2017 | 559 | 0.030 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2013 | 136 | 0.030 |
Why?
| Promoter Regions, Genetic | 1 | 2017 | 1195 | 0.030 |
Why?
| Phosphoproteins | 1 | 2015 | 326 | 0.030 |
Why?
| Algorithms | 1 | 2020 | 1632 | 0.030 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 2013 | 326 | 0.030 |
Why?
| HLA-DR Antigens | 1 | 2013 | 226 | 0.030 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 395 | 0.020 |
Why?
| Catalysis | 1 | 2013 | 307 | 0.020 |
Why?
| Monocytes | 1 | 2015 | 554 | 0.020 |
Why?
| Reproducibility of Results | 1 | 2020 | 3054 | 0.020 |
Why?
| Inflammation Mediators | 1 | 2015 | 504 | 0.020 |
Why?
| Colorado | 1 | 2022 | 4471 | 0.020 |
Why?
| Glutathione | 1 | 2013 | 333 | 0.020 |
Why?
| Tubulin | 1 | 2012 | 131 | 0.020 |
Why?
| Neural Stem Cells | 1 | 2012 | 132 | 0.020 |
Why?
| Acetylation | 1 | 2011 | 235 | 0.020 |
Why?
| RNA Interference | 1 | 2012 | 448 | 0.020 |
Why?
| Mice, Inbred C57BL | 1 | 2021 | 5279 | 0.020 |
Why?
| c-Mer Tyrosine Kinase | 1 | 2010 | 44 | 0.020 |
Why?
| Choroid Plexus Neoplasms | 1 | 2009 | 9 | 0.020 |
Why?
| Papilloma | 1 | 2009 | 46 | 0.020 |
Why?
| Zebrafish | 1 | 2014 | 448 | 0.020 |
Why?
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2009 | 13 | 0.020 |
Why?
| Kinetics | 1 | 2013 | 1620 | 0.020 |
Why?
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2009 | 40 | 0.020 |
Why?
| Immunoglobulin Heavy Chains | 1 | 2009 | 80 | 0.020 |
Why?
| Epilepsy | 1 | 2013 | 314 | 0.020 |
Why?
| Gene Knockdown Techniques | 1 | 2010 | 315 | 0.020 |
Why?
| Antibodies, Neoplasm | 1 | 2009 | 35 | 0.020 |
Why?
| Single-Blind Method | 1 | 2009 | 275 | 0.020 |
Why?
| Claudins | 1 | 2009 | 25 | 0.020 |
Why?
| Cytogenetics | 1 | 2008 | 12 | 0.020 |
Why?
| Virus Replication | 1 | 2011 | 449 | 0.020 |
Why?
| Leukocytes, Mononuclear | 1 | 2011 | 543 | 0.020 |
Why?
| DNA Repair | 1 | 2009 | 208 | 0.020 |
Why?
| Paresis | 1 | 2007 | 30 | 0.020 |
Why?
| Inflammation | 1 | 2018 | 2705 | 0.020 |
Why?
| Biopsy | 1 | 2010 | 1098 | 0.020 |
Why?
| Hypothalamic Neoplasms | 1 | 2006 | 9 | 0.020 |
Why?
| Craniotomy | 1 | 2007 | 69 | 0.020 |
Why?
| Microscopy, Electron | 1 | 2007 | 418 | 0.020 |
Why?
| Multigene Family | 1 | 2007 | 197 | 0.020 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2013 | 2071 | 0.020 |
Why?
| Vision Disorders | 1 | 2007 | 133 | 0.020 |
Why?
| Genetic Linkage | 1 | 2006 | 298 | 0.020 |
Why?
| Genetic Markers | 1 | 2006 | 335 | 0.020 |
Why?
| Neural Crest | 1 | 2006 | 120 | 0.020 |
Why?
| Data Interpretation, Statistical | 1 | 2007 | 338 | 0.020 |
Why?
| Caspase 3 | 1 | 2004 | 242 | 0.010 |
Why?
| Enzyme Activation | 1 | 2004 | 812 | 0.010 |
Why?
| Aged, 80 and over | 1 | 2013 | 7074 | 0.010 |
Why?
| Brain | 1 | 2013 | 2596 | 0.010 |
Why?
| Genetic Predisposition to Disease | 1 | 2006 | 2272 | 0.010 |
Why?
| Time Factors | 1 | 2008 | 6593 | 0.010 |
Why?
| Neoplasms | 1 | 2008 | 2435 | 0.010 |
Why?
|
|
Donson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|